-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
Endometriosis test backed by French government under scrutiny
When France launched its strategy to fight endometriosis in 2022, it widely promoted a simple saliva test that was promised to revolutionise diagnosis of the little-understood disease, which causes debilitating pain in women across the world.
However, after years of financial support from the government, significant questions remain about the effectiveness of the "Endotest" developed by French start-up Ziwig, several researchers have told AFP.
There is no doubt a better test for endometriosis would represent a major medical breakthrough. The chronic disease, in which tissue similar to the lining of the uterus grows outside the womb, affects at least one in 10 women of reproductive age worldwide, significantly raising their risk of infertility.
Yet women often endure a long and difficult journey to diagnose endometriosis, which can currently only be confirmed by an invasive surgical procedure requiring general anaesthesia.
A saliva sample is all that is required for the Endotest, which is marketed as using artificial intelligence and new microRNA technology to diagnose the disease.
Ziwig's founders have vowed a "revolution" that would enable "early detection of all forms of endometriosis, even the most complex".
If successful, this would also mark a meaningful scientific advance -- though the discovery of microRNA in the 1990s earned a medicine Nobel last year, the technology has yet to lead to a significantly impactful pharmaceutical product.
The government's support for the Endotest has not wavered, even during a turbulent few years in French politics.
"The Ziwig project embodies French excellence in medical innovation," former health minister Genevieve Darrieussecq said last year.
Current Health Minister Catherine Vautrin, who visited Lyon-based Ziwig's lab earlier this year, is quoted promoting the test on the start-up's website -- unusual in the biotech sector.
The government also pays to reimburse patients getting the test, a move estimated to cost taxpayers 21 million euros ($25 million).
- What does the research show? -
When Ziwig promotes the test's effectiveness, it normally cites two studies in scientific journals.
One, published in the Journal of Clinical Medicine in 2022, was "only a starting point", according to Kevin McConway, a professor of applied statistics at Britain's Open University.
The other, published in NEJM Evidence in 2023, represented a "useful step along the way", but is not "on its own an adequate external validation" of the test's effectiveness, McConway told AFP.
Other experts said the participants in the research may not be representative. For example, the first study was based on 200 people in France who were already considered likely to have endometriosis.
"Can we generalise a tool that was based on only one population?" asked Bianca Schor, a women's health researcher at Amsterdam University Medical Center.
In evaluating who should be reimbursed for the test, the independent French Health Authority (HAS) said in 2023 that the Endotest demonstrated "validated diagnostic performance".
However, the authority added that another study was needed to "demonstrate its clinical utility".
And rather than recommending the Endotest to detect the disease early -- as it was intended to do -- the authority only reimburses the test after other imaging techniques have failed, as a way to avoid surgery.
- Other avenues ignored? -
Some specialists pointed out that the government is spending just 11 million euros ($13 million) on endometriosis research under its women's health programme, which is around half the amount going to the Endotest.
Ludivine Doridot, a professor at French research organisation Inserm and a coordinator of the programme, criticised this disparity.
"This will not help other companies develop technologies that could have a positive impact in the future," she said.
Other avenues to help diagnose endometriosis, such as improving how ultrasound scans are interpreted, also deserve public support, she added.
France's health ministry did not respond to AFP's request for comment.
Ziwig's president and co-founder Yahya El Mir defended the Endotest.
"There is no other product worldwide that has this quality," he told AFP, maintaining that the published research provides enough evidence of its effectiveness.
Leading scientific journals have also been approached to review Ziwig's clinical data, but this process "takes time", he added.
What do patients think? The French patient advocacy group Endomind has campaigned to make the Endotest available for all patients.
However, Arounie Tavenet, an endometriosis patient and former member of the committee responsible for the government's national strategy, was more critical.
"We could have hoped for accelerated processes for what is presented as a national priority -- rather than exaggeratedly supporting the evaluation of a saliva test that raises ethical concerns and, ultimately, does not represent a major advance for patients," she said.
M.Robinson--AT